Re-operation for the treatment of well differentiated thyroid cancer: necessity, safety and impaction on further management.
نویسندگان
چکیده
BACKGROUND The diagnosis of thyroid carcinoma during the course of lobectomy for a dominant nodule occasionally cannot be rendered on the basis of frozen section. Once the diagnosis of carcinoma is made, the question of completion thyroidectomy arises. PATIENTS AND METHODS During a period of 3 years, 28 patients diagnosed with well-differentiated thyroid cancer (WDTC), and operated upon with less than total thyroidectomy, were admitted to our department. Patients had no clinical or radiological evidence of any residual disease at the time of admission. All were submitted for total thyroidectomy. RESULTS There were 7 men and 21 women (1:3), and the average age was 38.6+/-1.3 years (range, 20 to 62 years). The postoperative morbidity in completion thyroidectomy consisted of transient hypoparathyroidism in 2 patients (7.1 %), permanent hypoparathyroidism in 1 patient (3.5%), there was no recurrent laryngeal nerve palsy, there were haematoma in 2 patients, and seroma in 1 patient. Completion thyroidectomy resulted in detecting 9 patients (32.1%) having residual disease that was not clinically manifest. CONCLUSION Although many surgeons advocate total or near-total thyroidectomy for differentiated thyroid carcinoma, some of these surgeons hesitate to complete thyroidectomy after lobectomy for thyroid nodule when there is no clinical evidence to suggest bilateral disease, for fear of added morbidity to the patients. However, as demonstrated in this study, completion thyroidectomy was shown to be a fairly safe procedure, which carries a low incidence of complications. It also facilitates further management and follow-up with radioactive iodine. The decision to perform completion thyroidectomy for WDTC should be based on the patient's risk category, and not on a concern for risk of complications from the second procedure.
منابع مشابه
Incidence of thyroid papillary cancer in contralateral lobe
Background & objectives: Prognosis of thyroid papillary cancer is quite well long lasting, so a 10- year survival is observed in more than 90% cases. In this study, rate of incidence of thyroid papillary cancer in contralateral lobe was assessed among patients who had a surgical thyroidectomy re-operation. Materials & Methods: In this retrospective study, we examined 82 patients diagnosed with...
متن کاملI-124 pre-therapy dosimetry for the treatment of differentiated thyroid cancer: A single center experience
Introduction:The maximum tolerable activity (MTA) of I-131 in radioiodine therapy is an established surrogate quantity to ensure that the therapeutic activity does not produce severe damages to the bone marrow and lung. The aim of this study was to estimate the MTAs for high-risk patients using I-124 pre-therapy dosimetry and to compare the results with published literature. <...
متن کاملThe role of radiotherapy and chemotherapy in management of thyroid tumors [Persian]
Radioiodine (1-131) is the treatment of choice in differentiated thyroid carcinoma. External radiotlierapy however, has it's own roie in these tumors. Treatment of anaplastic thyroid carcinoma 1ms not acliieved any notahle success yet, though combined - modality regimens of radiotherapy and chemotherapy have sometimes shown significant results. In this paper the rol...
متن کاملFactors affecting discharge time of well differentiated thyroid cancer patients receiving 131I therapy: Five years’ experience
Introduction:The post-surgical management of patients with differentiated thyroid cancer include ablation of remnant local and distant metastatic tissues with 131I therapy, which accentuates isolation of the patient in order to avoid unnecessary radiation exposure to the care givers, general public and the environment. The duration of isolation is subject to the redu...
متن کاملThyroid hormone replacement one day before 131I therapy in patients with well-differentiated thyroid cancer
Objective: The current study aimed to determine the efficacy of radioiodine-131 (131I) ablation therapy with thyroid hormone replacement one day before 131I administration in patients with well-differentiated thyroid cancer (DTC). Methods: This retrospective study included 29 patients who underwent 131I therapies twice for DTC during 6-12 months. Since all the patients obviously had residual l...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
عنوان ژورنال:
- Journal of the Egyptian National Cancer Institute
دوره 16 3 شماره
صفحات -
تاریخ انتشار 2004